Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insights, Forecast to 2029
This report presents an overview of global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc.
By Company
- BioMarin Pharmaceutical
- Sangamo Therapeutics
- Amicus Therapeutics
- Roche
- Pfizer
- NightstaRx
- MeiraGTx
- Sarepta Therapeutics
- Neurocrine Biosciences
- Voyager Therapeutics
- Asklepios Biopharmaceutical
- Single-stranded AAV (ssAAV)
- Self-complementary AAV (scAAV)
- Hemophilia
- Ophthalmology
- Lysosomal Storage Disorders
- Neurological Disorders
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Head office and Area Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY TYPE
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
6.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
6.2.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
6.2.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
6.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
6.3.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
6.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
6.4.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
7.2.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
7.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
7.2.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
7.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
7.3.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
7.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
7.4.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
8.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
8.2.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
8.2.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
8.2.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
8.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
8.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
8.3.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
8.3.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
9.2.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
9.2.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
9.2.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
9.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
9.3.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
9.3.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
9.3.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9.4 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
9.4.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)
9.4.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Details
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.1.5 BioMarin Pharmaceutical Recent Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Details
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.2.5 Sangamo Therapeutics Recent Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Details
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.3.5 Amicus Therapeutics Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.4.5 Roche Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.5.5 Pfizer Recent Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Details
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.6.5 NightstaRx Recent Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Details
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.7.5 MeiraGTx Recent Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Details
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.8.5 Sarepta Therapeutics Recent Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Details
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.9.5 Neurocrine Biosciences Recent Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Details
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.10.5 Voyager Therapeutics Recent Developments
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Details
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.11.5 Asklepios Biopharmaceutical Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Head office and Area Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY TYPE
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
6.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
6.2.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
6.2.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
6.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
6.3.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
6.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
6.4.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
7.2.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
7.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
7.2.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
7.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
7.3.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
7.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
7.4.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
8.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
8.2.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
8.2.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
8.2.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
8.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
8.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
8.3.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
8.3.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
9.2.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
9.2.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
9.2.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
9.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
9.3.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
9.3.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
9.3.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9.4 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
9.4.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)
9.4.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Details
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.1.5 BioMarin Pharmaceutical Recent Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Details
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.2.5 Sangamo Therapeutics Recent Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Details
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.3.5 Amicus Therapeutics Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.4.5 Roche Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.5.5 Pfizer Recent Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Details
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.6.5 NightstaRx Recent Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Details
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.7.5 MeiraGTx Recent Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Details
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.8.5 Sarepta Therapeutics Recent Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Details
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.9.5 Neurocrine Biosciences Recent Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Details
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.10.5 Voyager Therapeutics Recent Developments
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Details
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.11.5 Asklepios Biopharmaceutical Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Single-stranded AAV (ssAAV)
Table 3. Key Players of Self-complementary AAV (scAAV)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2023)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)
Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players (2018-2023)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Headquarters and Area Served
Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2023)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2018-2023)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2024-2029)
Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 63. BioMarin Pharmaceutical Company Details
Table 64. BioMarin Pharmaceutical Business Overview
Table 65. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 66. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 67. BioMarin Pharmaceutical Recent Developments
Table 68. Sangamo Therapeutics Company Details
Table 69. Sangamo Therapeutics Business Overview
Table 70. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 71. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 72. Sangamo Therapeutics Recent Developments
Table 73. Amicus Therapeutics Company Details
Table 74. Amicus Therapeutics Business Overview
Table 75. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 76. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 77. Amicus Therapeutics Recent Developments
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 81. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 82. Roche Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 86. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. NightstaRx Company Details
Table 89. NightstaRx Business Overview
Table 90. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 91. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 92. NightstaRx Recent Developments
Table 93. MeiraGTx Company Details
Table 94. MeiraGTx Business Overview
Table 95. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 96. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 97. MeiraGTx Recent Developments
Table 98. Sarepta Therapeutics Company Details
Table 99. Sarepta Therapeutics Business Overview
Table 100. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 101. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 102. Sarepta Therapeutics Recent Developments
Table 103. Neurocrine Biosciences Company Details
Table 104. Neurocrine Biosciences Business Overview
Table 105. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 106. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 107. Neurocrine Biosciences Recent Developments
Table 108. Voyager Therapeutics Company Details
Table 109. Voyager Therapeutics Business Overview
Table 110. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 111. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 112. Voyager Therapeutics Recent Developments
Table 113. Asklepios Biopharmaceutical Company Details
Table 114. Asklepios Biopharmaceutical Business Overview
Table 115. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 116. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 117. Asklepios Biopharmaceutical Recent Developments
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Single-stranded AAV (ssAAV)
Table 3. Key Players of Self-complementary AAV (scAAV)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2023)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)
Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players (2018-2023)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Headquarters and Area Served
Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2023)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2018-2023)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2024-2029)
Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 63. BioMarin Pharmaceutical Company Details
Table 64. BioMarin Pharmaceutical Business Overview
Table 65. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 66. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 67. BioMarin Pharmaceutical Recent Developments
Table 68. Sangamo Therapeutics Company Details
Table 69. Sangamo Therapeutics Business Overview
Table 70. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 71. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 72. Sangamo Therapeutics Recent Developments
Table 73. Amicus Therapeutics Company Details
Table 74. Amicus Therapeutics Business Overview
Table 75. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 76. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 77. Amicus Therapeutics Recent Developments
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 81. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 82. Roche Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 86. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. NightstaRx Company Details
Table 89. NightstaRx Business Overview
Table 90. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 91. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 92. NightstaRx Recent Developments
Table 93. MeiraGTx Company Details
Table 94. MeiraGTx Business Overview
Table 95. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 96. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 97. MeiraGTx Recent Developments
Table 98. Sarepta Therapeutics Company Details
Table 99. Sarepta Therapeutics Business Overview
Table 100. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 101. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 102. Sarepta Therapeutics Recent Developments
Table 103. Neurocrine Biosciences Company Details
Table 104. Neurocrine Biosciences Business Overview
Table 105. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 106. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 107. Neurocrine Biosciences Recent Developments
Table 108. Voyager Therapeutics Company Details
Table 109. Voyager Therapeutics Business Overview
Table 110. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 111. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 112. Voyager Therapeutics Recent Developments
Table 113. Asklepios Biopharmaceutical Company Details
Table 114. Asklepios Biopharmaceutical Business Overview
Table 115. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 116. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 117. Asklepios Biopharmaceutical Recent Developments
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029
Figure 3. Single-stranded AAV (ssAAV) Features
Figure 4. Self-complementary AAV (scAAV) Features
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029
Figure 7. Hemophilia Case Studies
Figure 8. Ophthalmology Case Studies
Figure 9. Lysosomal Storage Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022
Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 21. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 22. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 23. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 27. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 28. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 29. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 37. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 38. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 40. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 41. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)
Figure 42. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 52. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 59. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 60. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 61. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 62. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 63. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 64. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 65. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 66. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 67. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 68. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029
Figure 3. Single-stranded AAV (ssAAV) Features
Figure 4. Self-complementary AAV (scAAV) Features
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029
Figure 7. Hemophilia Case Studies
Figure 8. Ophthalmology Case Studies
Figure 9. Lysosomal Storage Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022
Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 21. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 22. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 23. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 27. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 28. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 29. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 37. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 38. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 40. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 41. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)
Figure 42. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 52. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 59. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 60. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 61. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 62. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 63. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 64. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 65. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 66. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 67. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 68. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
